Robert Imel, DO
Pulmonary Disease · Saint Cloud, MNNPI 1154850592
Payments from drug & device makers
Across 15 payments — averaging $104.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Boehringer Ingelheim$94
- La Jolla Pharmaceutical Company$47
- Regeneron Healthcare Solutions, Inc.$29
- Gilead$28
- GSK$21
- plus $28 from 2 others
What the payments were for
- Travel & lodging$1,32284%
- Food & beverage$24716%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $1,322 |
| Boehringer Ingelheim | 2 | $94 |
| La Jolla Pharmaceutical Company | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Gilead | 2 | $28 |
| GSK | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,303
How this compares
$1,568 in reported general payments places this provider in the 70th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 179 | $130,146 |
| Fasenra PenBenralizumab | 13 | $73,697 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $29,303 |
| Incruse ElliptaUmeclidinium Bromide | 59 | $22,284 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $13,020 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $10,813 |
| Spiriva RespimatTiotropium Bromide | 19 | $10,764 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $9,581 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,964 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,446 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $6,813 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,899 |
| Varenicline Tartrate | 12 | $1,493 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,355 |
| Montelukast Sodium | 70 | $1,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $21 | $189,698327 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $94 | $16,66330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 261 pulmonary disease providers in Minnesota.
Other pulmonary disease in Saint Cloud
- Justin StocksSaint Cloud$4K
- Charlene McEvoySaint Paul$8.4M
- Ulrich SpecksRochester$2.6M
- Teng MouaRochester$2.4M
- Hyun KimMinneapolis$1.5M
- Joanne BillingsMinneapolis$1.5M
- Vivek IyerRochester$1.2M
- Timothy AksamitRochester$982K
- Patrick WrightMinneapolis$817K
- Jonathan HovdaMinneapolis$713K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.